Identification of a Raloxifene Analog That Promotes AhR-Mediated Apoptosis in Cancer Cells
Hyo Sang Jang1, Martin Pearce2, Edmond F O'Donnell3
1Cancer Research Laboratory, Department of Environmental and Molecular Toxicology, Oregon State University, Corvallis, OR 97331, USA. janghy@oregonstate.edu.
Biology
|December 2, 2017
Summary
A novel raloxifene analog, Y134, effectively targets the aryl hydrocarbon receptor (AhR) to induce cancer cell death. Y134 demonstrates improved safety compared to raloxifene, showing potential as a new anti-cancer therapeutic.
Area of Science:
- Pharmacology
- Cancer Biology
- Medicinal Chemistry
Background:
- Raloxifene, an estrogen receptor modulator, also interacts with the aryl hydrocarbon receptor (AhR).
- Raloxifene induces apoptosis in cancer cells via AhR activation.
- Understanding raloxifene's structural requirements for AhR activity is crucial for developing targeted therapies.
Purpose of the Study:
- To investigate structure-activity relationships of raloxifene analogs for AhR-mediated transcriptional activity and apoptosis.
- To identify novel raloxifene analogs with anti-cancer potential targeting the AhR.
- To evaluate the safety profile of promising analogs.
Main Methods:
- Structure-activity relationship studies of seven raloxifene analogs.
- Assays for AhR-mediated transcriptional activity and apoptosis induction in cancer cell lines (MDA-MB-231, hepatoma cells).
- Zebrafish embryo toxicity testing to assess safety profiles.
Main Results:
- Y134, a raloxifene analog, activates AhR and induces apoptosis in triple-negative breast cancer cells (MDA-MB-231).
- AhR suppression significantly reduced Y134-induced apoptosis, confirming AhR's role.
- Y134 demonstrated a better safety profile in zebrafish embryos compared to raloxifene.
- A partial AhR antagonist analog was also identified, capable of inhibiting AhR agonist activity.
Conclusions:
- Y134 is a potent AhR agonist and inducer of apoptosis in cancer cells.
- Y134 exhibits a favorable safety profile, suggesting its potential as an anti-cancer agent.
- Further optimization of Y134 is warranted for developing novel AhR-targeted cancer therapies.
Related Concept Videos
01:31Transducer Mechanism: Nuclear Receptors
2.7K
Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
2.7K
02:57Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K